This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should Vanguard Russell 2000 ETF (VTWO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VTWO
Inspire Medical (INSP) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the first quarter.
Inspire Medical Systems (INSP) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 24.29% and 6.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers Health, Inc. (HIMS) Surges 10.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
What Makes Inspire (INSP) a New Buy Stock
by Zacks Equity Research
Inspire (INSP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Industry Outlook Highlights Inspire Medical Systems, Olink Holding and Health Catalyst
by Zacks Equity Research
Inspire Medical Systems, Olink Holding and Health Catalyst have been highlighted in this Industry Outlook article.
3 Medical Info Systems Stocks Countering Industry-wide Headwinds
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Inspire Medical Systems (INSP), Olink Holding (OLK) and Health Catalyst (HCAT) are expected to gain even as COVID-19 severity fades.
Should iShares Russell 2000 ETF (IWM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWM
Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWO
Best Momentum Stocks to Buy for February 21st
by Zacks Equity Research
INSP and BZLFY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 21, 2023.
New Strong Buy Stocks for February 21st
by Zacks Equity Research
EMBC, INSP, REPYY, BZLFY and CVI have been added to the Zacks Rank #1 (Strong Buy) List on February 21, 2023.
Best Momentum Stocks to Buy for February 17th
by Zacks Equity Research
INSP, ABNB and HLF made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 17, 2023.
New Strong Buy Stocks for February 17th
by Zacks Equity Research
KNBWY, INSP, HLF, VTNR and HBT have been added to the Zacks Rank #1 (Strong Buy) List on February 17, 2023.
Best Momentum Stocks to Buy for February 14th
by Zacks Equity Research
INSP and RL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 14, 2023.
New Strong Buy Stocks for February 14th
by Zacks Equity Research
INSP, ALK, SSKN, NVO and TBPH have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.
Molina Healthcare (MOH) Q4 Earnings Beat on Solid Medicaid Unit
by Zacks Equity Research
Molina Healthcare's (MOH) fourth-quarter results benefit from its strong Medicaid and Medicare businesses. Management expects 2023 adjusted EPS at a minimum of $19.75.
Inspire Medical (INSP) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the fourth quarter.
Inspire Medical Systems (INSP) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 118.52% and 0.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Should iShares Russell 2000 ETF (IWM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWM
Inspire Medical Systems (INSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Inspire (INSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inspire Medical Systems (INSP) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 20% and 14.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Inspire (INSP) Soars 7.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Inspire (INSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
3 Medical Info System Stocks to Gain on Rising Demand for Digital Health
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Inspire Medical Systems, Inc. (INSP), Axonics (AXNX), and Pulmonx Corporation (LUNG) are expected to gain on rising demand for telehealth.
Wall Street Analysts Believe Inspire (INSP) Could Rally 46%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 46.4% upside potential for Inspire (INSP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CareCloud, Inc. (MTBC) Surges 11%: Is This an Indication of Further Gains?
by Zacks Equity Research
CareCloud, Inc. (MTBC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.